Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG Imaging in Advanced NSCLC
NCT06107374Phase 2Recruiting
- Sponsor
- CellSight Technologies
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [18F]fluoro-arabinofuranosyl guanine in non-small cell lung cancer (NSCLC), sponsored by CellSight Technologies. Started Nov 2023; status: recruiting.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06107374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107374.